Objective: To investigate the effects of biologics on psychological status and quality of life in patients with inflammatory bowel disease (IBD). Methods: A cross-sectional survey was conducted in 42 hospitals in 22 provinces (autonomous regions and municipalities directly under the central government) from September 2021 to May 2022. General clinical information and the use of biologics were obtained from adult patients diagnosed with IBD who voluntarily participated in the study. Psychological status was evaluated using the Generalized Anxiety Disorder (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Pittsburgh Sleep Quality Index (PSQI), and Inflammatory Bowel Disease Questionnaire (IBDQ) assessment tools. Counts were analyzed via the Chi-square test, and datasets that were not normally distributed were analyzed via nonparametric tests. P<0.05 was considered statistically significant. Results: A total of 2 478 valid questionnaires were collected. The GAD-7 score of the biologics group was significantly lower than that of the non-use group [6 (2, 9) vs. 7 (3, 10), Z=-3.49, P<0.001]. IBDQ scores [183 (158, 204) vs. 178 (152, 198), Z=-4.11, P<0.001], intestinal symptom scores [61 (52, 67) vs. 58 (49, 65), Z=-5.41, P<0.001], systemic symptom scores [28 (24, 32) vs. 27 (23, 31), Z=-2.37, P=0.018], emotional ability scores [69 (58, 77) vs. 67 (56, 75), Z=-3.58, P<0.001] and social ability scores [26 (22, 29) vs. 25 (22, 29), Z=-2.52, P=0.012] in the biologics group were significantly higher than in the non-use group. GAD-7 scores [5 (2, 9) vs. 6 (3, 10), Z=-3.50, P<0.001] and PSQI scores [6 (4, 9) vs. 6 (4, 9), Z=-2.55, P=0.011] were significantly lower in the group using infliximab than in the group not using it. IBDQ scores were significantly higher in patients using vedolizumab than in those not using it [186 (159, 205) vs. 181 (155, 201), Z=-2.32, P=0.021] and were also significantly higher in the group treated with adalimumab than in the group not treated with adalimumab [187 (159, 209) vs. 181 (155, 201), Z=-2.16, P=0.030]. However, ustekinumab had no significant effect on any of the scores. Conclusion: The use of biologics is strongly associated with improvements in anxiety status and quality of life in IBD patients.
目的： 探讨生物制剂对炎症性肠病（IBD）患者心理状态和生活质量的影响。 方法： 横断面研究。于2021年9月至2022年5月在全国22个省（自治区、直辖市）的42家医院进行横断面调查研究。收集自愿参与调研的确诊IBD成人患者的一般临床资料和生物制剂使用情况，采用广泛性焦虑障碍量表（GAD-7）、抑郁症筛查量表（PHQ-9）、匹兹堡睡眠质量指数（PSQI）和IBD生活质量量表（IBDQ）进行心理状态评估。计数资料采用χ2检验，计量资料不满足正态分布，采用非参数检验。P<0.05为差异有统计学意义。 结果： 共回收有效问卷2 478份。使用生物制剂的患者GAD-7评分显著低于未使用生物制剂的IBD患者［（6（2，9）比 7（3，10）分，Z=-3.49，P<0.001］。生物制剂治疗组的IBDQ评分［183（158，204）比 178（152，198）分，Z=-4.11，P<0.001］、肠道症状评分［61（52，67）比 58（49，65）分，Z=-5.41，P<0.001］、全身症状评分［28（24，32）比 27（23，31）分，Z=-2.37，P=0.018］、情感能力评分［69（58，77）比 67（56，75）分，Z=-3.58，P<0.001］以及社会能力评分［26（22，29）比 25（22，29）分，Z=-2.52，P=0.012］均显著高于未使用生物制剂组。使用英夫利西单抗组的GAD-7评分［5（2，9）比 6（3，10）分，Z=-3.50，P<0.001］和PSQI评分［6（4，9）比 6（4，9），Z=-2.55，P=0.011］均显著低于未使用组。使用维得利珠单抗的患者IBDQ评分显著高于未使用的患者［186（159，205）比 181（155，201）分，Z=-2.32，P=0.021］，并且使用阿达木单抗治疗组的IBDQ评分也明显高于未使用组［187（159，209）比 181（155，201）分，Z=-2.16，P=0.030］。而乌司奴单抗对各项评分均无显著影响。 结论： 生物制剂的使用与IBD患者焦虑状态和生活质量的改善密切相关。.